Clovis Oncology

Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology.[1] Clovis was founded in 2009 and is headquartered in Boulder, Colorado.[2] The company is a publicly traded company on NASDAQ under the symbol "CLVS"[3] and is in the NASDAQ Biotechnology Index[4] with several products in its product pipeline.[5] As of December 31, 2017 the company was not profitable and had incurred losses in each year since its inception in April 2009.[6]

Clovis Oncology
NASDAQ: CLVS
Russell 2000 Component

Pipeline

Its products include:

Rociletinib

The company was developing rociletinib,[7] as a treatment for non-small cell lung cancer.[1][8][9][10] A phase III trial was completed in April 2016[11] and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib).[11] According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment.[12]

In September 2018, the company and two former executives agreed to a $20M settlement with the Securities and Exchange Commission on claims it exaggerated to investors the efficacy of Roci in patient trials.[13][14]

Rucaparib

Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer.[15]

Lucitanib

Lucitanib is a VEGFR inhibitor.[16] it is also an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors.[17]

References
  1. "Clovis Oncology: A Winning Or Losing Lottery Ticket?". Forbes. 2015-11-16. Retrieved 2016-01-04.
  2. "CLVS Profile". finance.yahoo.com.
  3. "Clovis Oncology Inc". www.marketwatch.com. Retrieved 4 January 2016.
  4. "Overview NBI". nasdaq.com. Retrieved 4 January 2016.
  5. "Clovis Oncology - Products & Companion Diagnostics". Clovisoncology.com. 9 March 2015. Archived from the original on March 9, 2015. Retrieved 4 January 2016.
  6. Clovis Oncology, Inc. Form 10-K for the fiscal year ended December 31, 2017.
  7. Williams, Sean (23 December 2015). "A Festivus for the Invest in Us -- It's Time for the Airing of Grievances". Fox Business. Retrieved 4 January 2016.
  8. Wallace, Alicia. "Clovis Oncology stock bludgeoned after delay in cancer drug approval". www.denverpost.com. Retrieved 4 January 2016.
  9. "Clovis Oncology Announces Regulatory Update for Rociletinib NDA Filing". www.reuters.com. Archived from the original on 5 March 2016. Retrieved 4 January 2016.
  10. "FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC". OncLive. 2015-11-16. Retrieved 2016-01-04.
  11. Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%. April 2016
  12. "About Clovis". Retrieved 18 November 2016.
  13. "Clovis Oncology, execs to pay $20 million to settle SEC charges". Reuters. 2018-09-18. Retrieved 2018-09-28.
  14. "Clovis, CEO, Ex-CFO Agree to Pay $20M+ to Settle SEC Charges | GEN". GEN. Retrieved 2018-09-28.
  15. "Rucaparib at Clovis". Archived from the original on 2016-04-13. Retrieved 2016-04-05.
  16. "Lucitanib at Clovis". Archived from the original on 2016-04-14. Retrieved 2016-04-05.
  17. Soria; et al. (2014). "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". Annals of Oncology. 25 (11): 2244–51. doi:10.1093/annonc/mdu390. PMID 25193991.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.